Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments February 27, 2019
N4 Pharma Plc, a specialist pharmaceutical company, is developing Nuvec – a unique non-viral adjuvant delivery system for vaccines and...DNA VACCINE TECHNOLOGY – A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Inovio Develops Novel H3N2 Influenza DNA Vaccine; Generates Cross-Reactive Responses & Provides Complete Protection Against Lethal Preclinical Challenges September 20, 2018
Inovio Pharmaceuticals, Inc. recently announced its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses...Vaccinex & Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development November 30, 2017
Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag®...AELIX Therapeutics Enrolls First Patient in HIV Vaccine Trial September 11, 2017
AELIX Therapeutics recently announced that it has enrolled the first patient in its Phase 1 clinical trial for the assessment...Inovio’s DNA-Based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation July 7, 2017
Inovio Pharmaceuticals, Inc. recently announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection...Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study May 30, 2017
Inovio Pharmaceuticals, Inc. recently announced that its HIV vaccine, PENNVAX-GP, produced amongst the highest overall levels of immune response rates...PROTEIN THERAPEUTICS MARKET – Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
Cobra Biologics & Touchlight Collaborate on Production of Next-Generation DNA Constructs June 14, 2016
Cobra Biologics Ltd and Touchlight are collaborating on a project to optimize the manufacture of Adeno-Associated Virus (AAV) vectors used...Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion May 31, 2016
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC...Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines March 18, 2016
Inovio Pharmaceuticals, Inc. recently announced it has signed a definitive agreement to acquire all of Bioject Medical Technologies Inc.’s assets,...Inovio Pharmaceutical’s DNA Vaccine for Zika Virus Induces Robust Immune Responses February 22, 2016
Inovio Pharmaceuticals, Inc. recently announced that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable...BIOTHERAPEUTICS DEVELOPMENT – The Role of Flow Electroporation in Vaccine Development May 4, 2015
James Brady, PhD, Karen Donato, PhD, and Krista Steger, PhD, indicate that with unmatched quality, flexibility, and scalability, flow electroporation is a universal, cost-effective platform that supports the full range of biotherapeutic and vaccine development activities.
DNA VACCINES MARKET – DNA Vaccines: Strategic Markets & Emerging Technologies November 17, 2014
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
VACCINE TECHNOLOGY – Vaccine Technologies & the Rationale for New Nanoparticle Formulations October 3, 2014
Robert S. Becker, PhD, MBA, and Mark A. Mitchnick, MD, explain how SATx technology provides a new flexible formulation platform for the generation of nanoparticulate vaccine formulations without the limitations of previous formulation technologies that have inhibited the optimization of vaccine potencies and safety profiles.
Global Market for DNA Vaccines to Reach $2.7 Billion August 25, 2014
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...Global Market for DNA Vaccines to Reach $2.7 Billion August 21, 2014
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...Immune Response BioPharma to Develop In-House Sales Force for Blockbuster Vaccine August 12, 2014
New Jersey-based Immune Response BioPharma, Inc. recently announced its plans to create an in-house sales force for Remune, its HIV...Inovio’s Delivery Technology Powers Durable, Best-in-Class T-Cell Responses From HIV Vaccine July 18, 2013
Inovio Pharmaceuticals, Inc. recently announced the peer-reviewed publication of results from two Phase I trials (HVTN 070 and HVTN 080)...Prokarium Acquires Key Oral Vaccine Technology July 12, 2012
Prokarium Ltd recently announced it completed a key technology acquisition from Emergent BioSolutions Inc. The technology includes Emergent's live Salmonella-based...
